To analyze potential adverse drug events(ADEs) associated with ustekinumab and upadacitinib in the treatment of inflammatory bowel disease(IBD) based on an international authoritative database, thereby providing evidence for clinical medication safety.

Objective:To develop and evaluate the efficacy and safety of a three-dimensional (3D) digestive endoscope for gastric endoscopic submucosal dissection (ESD) through animal experiments.Methods:Two Dutch pigs were utilized from the Zhengzhou University Animal Experiment Center for the study. ESD procedures were performed by two senior endoscopists, one using 3D glasses and the other utilizing a 3D high-definition head display. The success of ESD was assessed based on predefined criteria, including completion of surgical steps, complete detachment of the presumptive lesion, and effective bleeding control during and after the surgery. The number of successful procedures and incidences of perforation were recorded. The stereoscopic experience of the endoscopists, including both the primary endoscopist and the assistant, was also evaluated. Furthermore, the assessment encompassed any reported symptoms of eye discomfort, such as eye fatigue, ocular pain, and blurred vision. Additionally, the confidence level of the endoscopists in the mechanical aspects of the operation, as well as encountered issues during the endoscopic procedures, were documented.Results:Two ESD were successful and no perforation occurred. Feedback from endoscopists suggested that 3D digestive endoscopy offered clear images with enhanced three-dimensionality during surgery, clear sense of distance and layering, allowing for a precise judgment of bleeding points, which surpassed 2D capabilities. No eye discomfort was experienced by endoscopists or assistants during or after the procedures. While endoscopists exhibited high confidence in 3D digestive endoscopy, they noted issues with image blurring when the camera was positioned less than 10 mm from the gastrointestinal tract wall.Conclusion:Preliminary results show that 3D digestive endoscopes can provide excellent stereo imaging, improved positioning accuracy, and safety during live animal stomach ESD procedures, without significantly increasing endoscopists' eye discomfort. Nevertheless, efforts are needed to address image blurring concerns when the camera is close to the gastrointestinal tract wall.

Background: Hemangioma is a vasogenic benign tumor commonly seen in the head and neck. However, it is rare in gastrointestinal tract and can cause symptoms such as gastrointestinal bleeding and abdominal pain, and it also can be life-threatening in severe cases. Aims: To analyze the clinical characteristics, treatment, and prognosis of gastrointestinal hemangioma, and to provide appropriate therapy for the diagnosis and treatment of gastrointestinal hemangioma. Methods: The patients with gastrointestinal hemangioma from August 2011 to October 2021 at the First Affiliated Hospital of Zhengzhou University were collected, and the clinical data, examination results, treatment and prognosis were analyzed retrospectively. Results: A total of 51 patients with gastrointestinal hemangioma were included, the ratio of male to female was 1.43:1, and the average age was (46.2±19.2) years old. Single gastrointestinal hemangioma was found in 45 patients (88.24%), and 18 lesions (35.29%) were in the esophagus, followed by the stomach (15.69%), small intestine (15.69%), colon (11.76%), and rectum (9.80%). The majority of patients were asymptomatic (50.98%), while 15 patients (29.41%) were presented by gastrointestinal bleeding. Thirty-two patients (62.75%) underwent endoscopic treatment, including 25 patients underwent endoscopic mucosal resection (EMR), 6 patients underwent endoscopic submucosal dissection (ESD), and 1 patient underwent endoscopic ligation. Nineteen patients (37.25%) underwent surgical surgery, including 5 patients underwent transrectal lesion resection, 1 patient underwent small intestinal lesion resection and 13 patients underwent resection of digestive tract. All patients recovered well after surgery. The average follow-up period was (61±32) months. One patient relapsed 1 year after surgery, 4 patients died of other diseases, and the remaining patients did not occur tumor recurrence, and 5 patients were lost to follow-up. Conclusions: Gastrointestinal hemangioma is rare and has no specific clinical symptoms. Endoscopy is important for its diagnosis, and endoscopic therapy is safe and effective for patients with indications.